Use of Lysophosphatidic Acid in the Management of Benign and Malignant Ovarian Tumors
Overview
Oncology
Affiliations
Objective: To establish whether LPA determination improves the differentiation of benign from malignant ovarian tumors.
Methods: Total LPA and LPA species in the serum were determined using a novel method in 142 patients with ultrasound (US) suspecious ovarian tumors and in 78 healthy women. All women underwent determination of CA125 in the serum, a vaginal US examination and morphology scoring of the tumor.
Results: The levels of total LPA and its species in women with ovarian tumors were significantly higher from those in healthy women (p < 0.001). No significant difference was found in the levels of total LPA or any of its species between the women with benign and those with malignant ovarian tumors.
Conclusions: Determination of serum LPA would be an appropriate test for ovarian tumor presence, especially in women of reproductive age. The method however does not differentiate benign from malignant ovarian tumors.
Challenges and Inconsistencies in Using Lysophosphatidic Acid as a Biomarker for Ovarian Cancer.
Yagi T, Shoaib M, Kuschner C, Nishikimi M, Becker L, Lee A Cancers (Basel). 2019; 11(4).
PMID: 30979045 PMC: 6521627. DOI: 10.3390/cancers11040520.
Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.
Li Y, Zhang W, Zhang J, Zheng C, Zhu H, Yu H Lipids Health Dis. 2015; 14:72.
PMID: 26174150 PMC: 4501043. DOI: 10.1186/s12944-015-0071-9.
Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.
Shan L, Chen Y, Davis L, Han G, Zhu W, Molina A PLoS One. 2012; 7(10):e46846.
PMID: 23082132 PMC: 3474784. DOI: 10.1371/journal.pone.0046846.
Quehenberger O, Dennis E N Engl J Med. 2011; 365(19):1812-23.
PMID: 22070478 PMC: 3412394. DOI: 10.1056/NEJMra1104901.
Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F J Gynecol Oncol. 2011; 21(4):248-54.
PMID: 21278887 PMC: 3026304. DOI: 10.3802/jgo.2010.21.4.248.